<DOC>
	<DOCNO>NCT00201812</DOCNO>
	<brief_summary>To determine safety efficacy combination Etanercept Docetaxel patient advance solid tumor standard treatment .</brief_summary>
	<brief_title>Phase I &amp; Biological Study Etanercept &amp; Weekly Docetaxel Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Must pathologically cytologically confirm advanced solid malignancy standard treatment exists . Solid malignancy persist recur follow prior therapy advance solid malignancy docetaxel consider acceptable first line treatment option : NonSmall Cell Lung Breast Head Neck Esophageal Stomach Ovarian carcinoma Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Life expectancy least 12 week . Must adequate organ function Peripheral Neuropathy must less Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>